Status:
UNKNOWN
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Melanoma
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Exploratory interventional study of prognostic serum biomarkers of cancer progression. Study of the relationship between the blood levels of soluble PDL1 and β2-microglobulin, and the clinical course...
Detailed Description
Primary objective To study the relationship between the blood levels of soluble PDL1 and β2-microglobulin measured at the diagnostic stage, and the clinical course of a metastatic solid tumor (non-sma...
Eligibility Criteria
Inclusion
- Adult patient, male or female, with metastatic cancer of the non-small cell, renal or malignant melanoma type, eligible for treatment with a first-line immune checkpoint inhibitor (immunotherapy alone or in combination with another immunotherapy, chemotherapy or targeted therapy).
- Affiliation to a Social Security organization
- Able to give informed consent to participate in research.
Exclusion
- Pregnant women
- Patient under guardianship, curatorship or legal protection
- Patient unable to understand the protocol (language barrier, cognitive difficulties)
- Patient with another active cancer
- Patient with creatinine clearance \<60 mL / min
- Patient participating in a therapeutic clinical trial
- Refusal of participation
Key Trial Info
Start Date :
February 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05426317
Start Date
February 10 2022
End Date
February 1 2024
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont-Ferrand
Clermont-Ferrand, France, 63000